The largest institutional shareholders of Novartis are understood to be willing to support a counter bid by the Swiss pharmaceutical group for Aventis, currently on the receiving end of a €43bn hostile bid from Sanofi-Synthélabo.

The move, by fund managers UBS asset management, Credit Suisse and JP Morgan Chase comes as cracks are beginning to appear in the support among Aventis' own shareholders for it to remain independent.